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After a well-coordinated series of randomized clinical trials conducted over the last 10 years, 
transcatheter aortic valve implantation (TAVI) is poised to emerge as the first-line treatment 
among patients with symptomatic severe aortic stenosis regardless of the estimated surgical 
risk1,2. Asides from bicuspid valve disease and understanding the true durability in younger 
patients, TAVIs effects upon conduction system and the subsequent longer-term 
consequences of these effects remain to be prospectively explored, representing the last 
frontier for this disruptive technology. 
Over time, TAVI has steadily overcome the numerous hurdles standing in its way.  
However, a few concerns remain going forwards. Among them, conduction disturbances (i.e. 
new-onset persistent left bundle branch block [LBBB] and permanent pacemaker implantation 
[PPI], represent the most common complications of this paradigm-changing therapy3. New-
onset LBBB has been reported in approximately 25% (4-65%) of first generation transcatheter 
heart valve recipients while data regarding its occurrence with newer-generation devices are 
relatively scarce with a reported incidence ranging from 10 to 70%3,4. Similarly, a wide 
variation in reported rates of PPI (2 to 51%) has been observed with first generation devices 
with a pooled incidence of 13%3. Of note, rates of PPI did not decrease with newer-generation 
devices3. Contrasting with this high incidence of conduction disturbances post-TAVR is the 
paucity of longer-term prospective data to better inform the impact upon subsequent PPI (for 
new-onset LBBB), heart failure hospitalisations and mortality. This latter point has been the 
subject of numerous individual studies reaching conflicting conclusions3,5–9. Several meta-
analyses failed to demonstrate a meaningful association between new-onset LBBB or PPI and 
all-cause mortality10,11. Nonetheless, a significant association between new-onset LBBB and 
an increased cardiac mortality was suggested, whereas PPI per se tended to associate with 
decreased cardiac mortality post-TAVI11. More recent studies unravelled conflicting results 
posing a conundrum, making it difficult for clinicians to accurately counsel patients when 
discussing the most appropriate therapeutic strategy to apply to those eligible both to TAVI or 
surgical aortic valve replacement (SAVR)5,7–9. Although post-TAVI rates of PPI are well 
within single-digit percentages in expert centres, and were comparable after SAVR and TAVI 
with a balloon-expandable valve in low-risk patients, the occurrence of new-onset LBBB 
remained more than 3-fold higher post-TAVI2. This issue is of paramount importance if TAVI 
is to ultimately succeed in even younger, healthier patients requiring aortic valve replacement 
in whom the detrimental consequences of conduction disturbances and right ventricular 
pacing could translate into deleterious cardiac outcomes. 
The path forwards leading to a more complete understanding of the long-term clinical 
impact of conduction disturbances post-TAVI remains somewhat cumbersome. Nonetheless, 
in this issue of the European Heart Journal, Faroux et al12 took another step towards this 
goal. The authors performed an updated systematic review and meta-analysis of studies 
reporting raw data on 1-year clinical impact of new-onset persistent LBBB or periprocedural 
PPI post-TAVI. The outcomes of interest included mortality (all-cause and cardiovascular), 
and rehospitalisation for heart failure for both complications as well as the need for PPI for 
new-onset LBBB. Thirty studies were deemed eligible for the analysis, including 12 studies 
(7792 patients) and 21 studies (42927 patients) for the assessment of the clinical impact of 
new-onset persistent LBBB, and PPI post-TAVI, respectively. New-onset LBBB was 
significantly associated with a higher 1-year risk of PPI, rehospitalisation for heart failure, all-
cause, and cardiovascular mortality. Similarly, PPI demonstrated a detrimental association 
with the 1-year risk of heart failure readmission, and all-cause mortality whereas no 
significant effect on cardiac death was observed. 
Meta-analyses, particularly those undertaken at a study-level, do not allow a stringent 
adjustment of confounders, and are inherently limited by the nuances of the included studies. 
Besides this limitation, its retrospective designs, along with varying definitions and selected 
time points for new-onset LBBB and PPI, a lack of ascertainment of the persistence of LBBB 
at the time of death, the different inter-study thresholds that prompted PPI, or exclusion of 
death within 30-days of the TAVI procedure in certain studies, represent a number of biases, 
which may have affected the results. The lack of data regarding baseline ejection fraction, 
type of pacemakers (acknowledged by authors), specific causes of death (e.g. sudden cardiac 
death), and the absence of granularity concerning pacing percentage at follow-up are other 
shortcomings that come to mind. Thus, the exact nature of the association between conduction 
disturbances and a worse prognosis post-TAVI remains elusive. However, despite these 
limitations, this study is at the very least thought-provoking. If the effects of post-TAVI 
conduction disturbances described by Faroux et al truly represent their genuine clinical 
impact, then we must pause and reflect upon the path forwards with TAVI12. As such, these 
findings warrant the analysis of robust prospective (even randomized in some cases) data of 
the incidence, natural history, and management of post-TAVI conduction disturbances. In 
particular, the exact role of electrophysiological studies, patch ECG recorders, and 
implantable loop recorders in the management of new-onset LBBB or transient high-degree 
atrioventricular block should be delineated (Take-home Figure). Moreover, some recent 
studies questioned the class effect of TAVI, suggesting that not all transcatheter heart valve’s 
designs are equal, especially regarding conduction disturbances13,14. Collectively, these 
observational data, along with the meta-analysis by Faroux et al12, should ultimately spur 
adequately-powered randomized comparisons of the commercially-available valves most 
commonly implanted in routine practice. Acknowledging that the risk of conduction 
disturbances cannot be the only decisional element, such data are urgently needed to inform 
clinician’s choice when facing patients suitable for most transcatheter heart valve designs. 
That being said, what should we be doing in the interim pending the availability of these 
prospective data, particularly over the longer term? Preventing or minimizing conduction 
disturbances during TAVI represents an important challenge in contemporary practice. 
Avoiding excessive prosthesis oversizing or manipulation, and aiming at a more aortic 
position are simple procedural features that may reduce their occurrence. In case of transient 
conduction disturbances post-TAVI, physicians should resist the urge for early PPI and adopt 
a watch and wait approach, even it means prolonging length of stay in some cases. Finally, 
despite a lack of prospective evidence, we should tend towards a more uniform management 
of conduction disturbances which has been advocated in a recent experts’ position paper4. 
Faroux et al should be commended for performing this work sending the cardiologic 
community a clear message: ‘Be careful!’ We cannot afford to neglect the issue of post-TAVI 
conduction disturbances anymore. 
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Take-home figure legend 
Summary of the potential clinical impact of post-TAVI conduction disturbances and 
future directions to prevent their occurrence and improve their management. 
EP: Electrophysiologists; EPS: Electrophysiological studies; HAVB: high-degree 
atrioventricular block; LBBB: left bundle branch block; LVEF: left ventricular ejection 
fraction; LVOT: left ventricular outflow tract; PPI: Permanent pacemaker implantation; 
TAVI: Transcatheter aortic valve implantation. 
 
 
 
 
 
 
 
  
 
 
 
 
 
